구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-NK cells |
Overview Company | Hangzhou Cheetah Cell Therapeutics Co., Ltd |
Overview Modality | CGT |
Overview Target | Safety and Efficacy |
Overview Indication | Safety and Efficacy |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.. An effective chimeric antigen receptor (CAR)-based immunotherapy depends on both a suitable immune cell platform and a tumor-specific antigen to overcome barriers in solid tumors. Natural killer (NK) cell lines are promising platforms for CAR constructs due to their inherent tumor-killing ability, safet… |
Toxicology CRS | Reported |
Clinical Safety signal | Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.. An effective chimeric antigen receptor (CAR)-based immunotherapy depends on both a suitable immune cell platform and a tumor-specific antigen to overcome barriers in solid tumors. Natural killer (NK) cell lines are promising platforms for CAR constructs due to their inherent tumor-killing ability, safet… |
Clinical Program phase | PRECLINICAL |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-NK cells |
Overview Company | Hangzhou Cheetah Cell Therapeutics Co., Ltd |
Overview Modality | CGT |
Overview Target | Safety and Efficacy |
Overview Indication | Safety and Efficacy |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.. An effective chimeric antigen receptor (CAR)-based immunotherapy depends on both a suitable immune cell platform and a tumor-specific antigen to overcome barriers in solid tumors. Natural killer (NK) cell lines are promising platforms for CAR constructs due to their inherent tumor-killing ability, safet… |
Toxicology CRS | Reported |
Clinical Safety signal | Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.. An effective chimeric antigen receptor (CAR)-based immunotherapy depends on both a suitable immune cell platform and a tumor-specific antigen to overcome barriers in solid tumors. Natural killer (NK) cell lines are promising platforms for CAR constructs due to their inherent tumor-killing ability, safet… |
Clinical Program phase | PRECLINICAL |
추천 비교
추천 비교